biotech

The FDA told Amgen to test whether a quarter-dose of sotorasib worked as well as the amount on the label. It did, but the biotech is sticking to the higher dose, which earns it an extra $180,000 a year per patient.

Florida may have prematurely demanded a $77.6 million refund from one of the taxpayer-backed biotech operations that a decade ago was supposed to help…